Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Perampanel Oral Suspension

Phase 2

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

PediatricActive, not recruiting

PediatricPhase 2

Active, not recruiting

Timeline

Expected Milestones

Q4 2027

Phase 2Active, not recruiting

Pediatric

NCT04015141

Clinical

Trials by Indication[1]

Pediatric1 trial

An Open-Label Study With Extension Phase to Evaluate the Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Subjects (Age 1 Month to Less Than 18 Years) With Childhood Epilepsy

Active, not recruiting· Eisai logo

Eisai·Phase 2·NCT04015141·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Perampanel Oral Suspension. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Perampanel Oral Suspension. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Eisai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Eisai

Related News